Anti-angiogenic agents (i.e., TKIs and anti-VEGF mAbs) and CPIs have been shown to improve survival in patients with advanced RCC (aRCC) and have become standard treatments for the management of this disease [6,7,8]. The gene discussed is VEGFA; the disease is renal cell carcinoma.